Forum 2026 is a premier invite-only event uniting top pharma and healthcare supply chain leaders. This exclusive platform explores cutting-edge innovations in AI, IoT, blockchain, and cold chain logistics, while fostering valuable networking and...
and biotechnology. Scheduled to take place on October 12–13, 2026, in Singapore, the conference serves as a global platform to exchange knowledge, discuss emerging trends, and foster collaborations that accelerate drug discovery and therapeutic...
Day: Celebrate breakthroughs and emerging players shaping the next generation of therapies. And More to Come: Fresh formats, dynamic networking experiences, and unique ways to connect across disciplines. Be part of the next chapter in life...
technologies and practical solutions. In this 8th edition as we explore the novel technologies and developments reforming pharmaceutical industry, we also dive deep into the implementation and advances in machine learning, deep learning, artificial...
2nd Annual MaxPotent Pharma Summit – a leading international platform bringing together senior executives, regulatory authorities, technology providers, and pharmaceutical innovators dedicated to advancing the future of Highly Potent Active...
for Open Innovation Bridging Human, Environment and Materials. The aim objective of ICCBS 2026 is to provide a platform for researchers, engineers, academicians as well as industrial professionals from all over the world to present their research...
under the theme “Nanotechnology for Tomorrow: Precision, Progress, and Possibilities”, is designed to provide a unique platform for interdisciplinary collaboration, where researchers, innovators, and industry leaders can explore the most recent...
relevant, addressing critical topics and fostering meaningful connections. This conference promises to be a pivotal platform for advancing knowledge and expanding professional networks.
pharma leaders Who Should Attend: Pharma marketing, digital, commercial, brand, patient engagement, innovation, and transformation leaders seeking practical strategies to stay ahead in a rapidly evolving landscape. Why Attend: Gain real-world...
We are pleased to invite and welcome you to attend 2026 16th International Conference on Bioscience, Biochemistry and Bioinformatics (ICBBB 2026) which will be held in Kobe, Japan during January 16-19, 2026. ICBBB 2026 is Co-Organized by Kobe...
sepsis is the most common cause of in-hospital deaths, costing over $62 billion annually in the USA alone. For more information please visit, www.sepsis.com
Sapio Sciences, the science-awareTM AI lab informatics platform, announced that the Wellcome Sanger Institute has selected the Sapio Informatics Platform as its central LIMS to underpin the Institute’s ambitious lab transformation program. The...
Medra, the company developing the first platform for Physical AI Scientists, announced a $52 million Series A financing led by Human Capital, with participation from existing investors Lux Capital, Neo, and NFDG, alongside new investors Catalio...
Kingdom, in Japan and Europe (27 countries of the European Union as well as Iceland, Liechtenstein and Norway). For more information please visit, www.servier.com
global expansion and reinforces its mission to bring real-time kidney data into clinical decision-making. By transforming urine output into a continuously measured and analysed digital parameter, FIZE enables clinicians to better assess kidney...
Agostino Gemelli in Rome, clinical experience is rapidly expanding across Europe. With around 80 procedures performed within a short timeframe in eight countries, MOVIVA® is helping to establish a new era of endoscopic bariatric treatment –...
Canada has approved Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg), in both vial and pre-filled syringe format, for treatment of all indications approved for Eylea. “Today’s approval lays a solid foundation for Celltrion’s expansion...
denosumab-containing medicinal products Hypercalcaemia in paediatric patients These highlights do not include all the information needed to use OBODENCE safely and effectively. Refer to the Summary of Product Characteristics for OBODENCE’s full...
and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, announced that the company will present new data related to ELZONRIS®...
entire treatment journey. The injection time for each LEQEMBI IQLIK autoinjector takes approximately 15 seconds. The SC formulation also has the potential to reduce healthcare resources associated with IV dosing, such as preparation for infusion...
